Fòs Feminista Remarks on U.S. Supreme Court’s Decision to Uphold Abortion Medication Access By Mail

New York, NY — Today, as the most recent administrative stay was set to expire, the Supreme Court blocked the U.S. Court of Appeals for the Fifth Circuit’s decision that was set to restrict the mailing of mifepristone, meaning that patients can still obtain the abortion and miscarriage care medication by mail or at a pharmacy after receiving care through telemedicine.

While Fòs Feminista is pleased the court did not restrict access to this safe, lifesaving care, we are concerned by seeing just how fragile access to abortion remains in the wake of Roe v. Wade being overturned in 2022 and how quickly people’s remaining rights can still be rolled back.

Attempting to restrict telemedicine access to mifepristone does not change the science. These actions only make care harder to reach, especially for people who already face the greatest barriers to care. For many women, girls, and gender-diverse people, telemedicine is not a convenience. It is a critical pathway to dignity, autonomy, and timely health care.

In response to today’s Supreme Court’s decision, Giselle Carino, CEO of Fòs Feminista, issued the following statement:

“While today we are grateful that people in the U.S. will not be cut off from accessing mifepristone, we also recognize that the conversations and decisions on sexual and reproductive health, rights, and justice in the U.S. have an impact around the world, as seen by the global impact of the U.S. Supreme Court decision in Dobbs.

“The need for a reliable supply of abortion medications and contraceptives, among other reproductive health commodities, is why we founded INNOVA Santé. Through INNOVA, we have worked to innovate and develop new, more affordable ways to produce and deliver mifepristone, as well as other sexual and reproductive supplies.”